A new Alzheimer’s drug was granted full approval by the Food and Drug Administration on Thursday, marking the first time the agency has approved a drug meant to slow the progression of the disease.
FILE - This Oct. 7, 2003 file photo shows a closeup of a human brain affected by Alzheimer's disease, on display at the Museum of Neuroanatomy at the University at Buffalo in Buffalo, N.Y. On Friday, Jan. 6, 2023, U.S. health officials approved Leqembi, a new Alzheimers drug that modestly slows the brain-robbing disease. The Food and Drug Administration granted the approval Friday for patients in the early stages of Alzheimer's.
The drug, called Leqembi, was shown in clinical trials to slow the progression of Alzheimer’s disease in people with mild cognitive impairment or early-stage illness. It is not a cure. to be one of the leading causes of the disease.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
FDA approves Alzheimer’s drug Leqembi, paving way for broader Medicare coverageLeqembi slowed cognitive decline in a clinical trial, but the treatment is expensive and carries serious risks of brain swelling and bleeding.
Baca lebih lajut »
Alzheimer’s drug Leqembi granted full FDA approvalUPDATE: U.S. officials granted full approval to a closely watched Alzheimer’s drug on Thursday, clearing the way for Medicare and other insurance plans to begin covering the treatment for people with the brain-robbing disease.
Baca lebih lajut »
Alzheimer’s drug Leqembi receives full FDA approvalThe Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer’s disease. It’s the first medicine that’s been convincingly shown to modestly slow Alzheimer’s cognitive decline.
Baca lebih lajut »
FDA Approves Promising New Alzheimer’s Drug LeqembiNot only is it the first Alzheimer’s antibody treatment to get full FDA approval, it’s also the first that will be broadly covered by Medicare.
Baca lebih lajut »
Alzheimer's drug Leqembi wins full FDA approvalThis clears the way for Medicare and other insurance plans to begin covering the treatment.
Baca lebih lajut »
First Alzheimer's drug to slow disease, Leqembi, gets full FDA approvalLeqembi is not a cure, but it is the first drug shown to slow the progression of Alzheimer's disease. It first received an accelerated approval from the FDA earlier this year.
Baca lebih lajut »